Abstract:T-cell acute lymphoblastic leukemias (T-ALL) are frequently associated with mutations in Notch 1, many of which lead to increased susceptibilities to cleavage by gamma secretase and generation of ICN1, promoting enhanced Notch1 signaling. Increased Notch1 activity in T-ALL was reported to indirectly repress transcription of PTEN, the major tumor suppressor involved in antagonizing PIP3-dependent cell signaling and in maintaining tight control over the pro-survival AKT pathway. While use of gamma secretase inhibitors (GSIs) prevents Notch1-activating cleavage and restores PTEN protein levels, a link between GSI treatments and PTEN posttranslational inactivation was also implied (Haematologica 95: 674-678, 2010). Phosphorylation by casein kinase II (CK2) of the S380/T382/3 cluster in the carboxyl-terminal region of PTEN is an efficient means of regulating PTEN activity, and of maintaining tight control over cell viability. PTEN phosphorylation impacts its cytosolic versus membrane localization, and PTEN protein stability and levels. However, the relative impact of Notch1 and GSIs on PTEN levels resulting from effects on PTEN transcription versus potential PTEN posttranslational effects has not been established. To begin to address this important question, we used conditional ectopic PTEN expression under control of a tetracycline-inducible promoter in PTEN-null Jurkat cells (designated Jkt/tet-onPten) to assess whether Notch1 can regulate PTEN posttranslationally. Cells were treated with doxycycline to induce PTEN, then with compound E (CompE), a potent GSI. CompE treatment increased phosphorylation of PTEN and AKT (S473 and T308), leading to elevated phosphorylation of GSK3αβ and S6RP downstream, consistent with inactivation of PTEN. This was accompanied by a moderate increase in cell proliferation. Analogous results were seen in Jkt/tet-onPten cells in which Notch1 was knocked down with a shRNA lentiviral vector (Jkt/tet-onPtenKD cells). Knockdown of Notch1 was accompanied by increased cytosolic localization of PTEN, consistent with its phosphorylation and inactivation. Treatment of Jkt/tet-onPtenKD cells with a CK2 inhibitor (tetrabromobenzimidazole) reduced PTEN phosphorylation and restored AKT activation, establishing that the effects of Notch1 on PTEN phosphorylation were via CK2. Our results suggest a mechanism whereby reduced Notch1 signaling in T-ALL cells increases PTEN posttranslational inactivation and AKT signaling, through an effect on CK2-mediated phosphorylation of PTEN. Although GSI treatment should transcriptionally increase PTEN levels, our data suggest that GSI treatment could potentially result in a more aggressive T-ALL due to increased PTEN inactivation and increased AKT signaling. Thus, combined use of a GSI with a downstream inhibitor to CK2, AKT or mTOR could provide significant benefit in treating T-ALL. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2881. doi:10.1158/1538-7445.AM2011-2881

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

Ezrin-radixin-moesin-binding Phosphoprotein-50 Regulates EGF-induced AKT Activation Through Interaction with EGFR and PTEN.

Regulation of the tumor suppressor PTEN by natural anticancer compounds

Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells

PTEN regulation by Akt-EGR1-ARF-PTEN axis.

PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase

Loss of PTEN Promotes Formation of Signaling-Capable Clathrin-Coated Pits

Targeting PTEN Regulation by Post Translational Modifications

Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells

Posttranslational Inactivation Of Pten Promoted By Loss Of Notchl Signaling In T-All

Protein Phosphatase Activity Of Pten Inhibited The Invasion Of Glioma Cells With Epidermal Growth Factor Receptor Mutation Type Iii Expression

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

TGF-β1 Induces Erlotinib Resistance in Non-Small Cell Lung Cancer by Down-Regulating PTEN

Loss of PTEN Expression Predicts Resistance to EGFR-targeted Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

PTPIP51 inhibits non-small-cell lung cancer by promoting PTEN-mediated EGFR degradation

Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling

PTEN decreases NR2F1 expression to inhibit ciliogenesis during EGFR L858R -induced lung cancer progression

Abstract 3053: PTEN as a double-edged sword regulates EGFRL858R-induced lung cancer progression

PTEN-mediated Resistance to Tyrosine Kinase Inhibitors in Lung Cancer Cell Lines H-157 and H-1355

Molecular Features of Phosphatase and Tensin Homolog (PTEN) Regulation by C-terminal Phosphorylation